UPDATED: Here's my updated list of compounders.NEW: $Cavco(CVCO)$$Cboe Global Markets, Inc(CBOE)$$CommVault(CVLT)$$Medpace(MEDP)$ Imagine having access to 15+ quality growth metrics for each of company (including cash return on capital, growth and valuation)?If that sounds interesting to you, then check this outImageyou can gain access to this spreadsheet and research notes - link below:ImageFor each company you get their share price linearity:ImageYou get the stability and expansion of their FCF marginsImageYou get their current valuation and their historic valuation... and so much more.Image
Summary Medpace Holdings is a US-based clinical research organization that is well-positioned to benefit from increased demand due to geopolitical risks affecting Chinese firms. Medpace stands out among its peers due to its growth orientation, competitive margins, and focus on next-generation therapies. While Medpace lacks diversification compared to WuXi Biologics, a pair trade strategy can help reduce risk and take advantage of the opportunities in the healthcare market. pengpeng/E+ via Getty Images Introduction Medpace Holdings (NASDAQ:MEDP) is a US-Based clinical research organization, or CRO. With distinct financials and growth orientation that place the firm well above the competition in the non-manufacturing space, it is clear that
Bullish Points: 1. For the six months ended June 30, 2023, the company reported net income of $133,962,000, compared to $110,671,000 for the same period in 2022. 2. Revenue for the six months ended June 30, 2023, was $894,942,000, compared to $682,154,000 for the same period in 2022. 3. Cash and cash equivalents increased to $39,138,000 as of June 30, 2023, compared to $28,265,000 as of December 31, 2022. 4. The company has approximately 5,600 employees across 41 countries as of June 30, 2023. 5. Major revenue sources include Oncology, Metabolic, Cardiology, Central Nervous System, and AVAI. 6. Net cash flows provided by operating activities were $162.6 million for the six months ended June 30, 2023. Bearish Points: 1. The company had short-term debt of $55,000,000, with principal payments
Hello everyone! Today I want to share some potential stocks with you! Hope it can be helpful to you!The stocks are as follow:Potential Cypher pattern developing on $F5网络(FFIV)$ . Projected price target 165.ImagePotential shark harmonic pattern developing on $Verizon(VZ)$ . Projected price target 52.ImagePotential deep crab harmonic pattern developing on $Medpace(MEDP)$ . Projected price target 287.ImagePotential bat harmonic pattern developing on $NextEra(NEE)$ Projected price target 86.ImagePotential AB=CD harmonic pattern developing on $Alaska Air(ALK)$ . Projected price target 12
CALX,MEDP,AGFS&CHX-4 very interesting post earnings chart
Bear markets have two components: Price and Time. Price takes your money. Time takes your patience; all those rallies that turn out not to be the beginning of a new bull market, even though so many people think/wish they were, eventually just wear almost everybody out.You grow so much more as a trader in technical execution, risk management, and emotional control from cycle of corrections, than periods of market rally.Turn up daily, embrace the experience. you will thrive eventually.There is unquestionable euphoria with positive market swing over the last few sessions, but the quality trades have already affirmed its relative strength in the first 2 weeks of the month. The best stocks bottom before the market4 very interesting post earnings chart in my watchlist:
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.